Shi Wenyin
Department of Radiation Oncology, Thomas Jefferson University, 111 South 11th Street, Suite G301, Philadelphia, PA 19107, USA.
Surg Oncol Clin N Am. 2015 Apr;24(2):323-35. doi: 10.1016/j.soc.2014.12.009. Epub 2015 Jan 21.
Although melanoma is generally considered a relative radioresistant tumor, radiation therapy (RT) remains a valid and effective treatment option in definitive, adjuvant, and palliative settings. Definitive RT is generally only used in inoperable patients. Despite a high-quality clinical trial showing adjuvant RT following lymphadenectomy in node-positive melanoma patients prevents local and regional recurrence, the role of adjuvant RT in the treatment of melanoma remains controversial and is underused. RT is highly effective in providing symptom palliation for metastatic melanoma. RT combined with new systemic options, such as immunotherapy, holds promise and is being actively evaluated.
尽管黑色素瘤通常被认为是一种相对抗拒放疗的肿瘤，但放射治疗（RT）在根治性、辅助性和姑息性治疗中仍然是一种有效的治疗选择。根治性放疗一般仅用于无法手术的患者。尽管一项高质量的临床试验表明，对淋巴结阳性的黑色素瘤患者进行淋巴结切除术后辅助放疗可预防局部和区域复发，但辅助放疗在黑色素瘤治疗中的作用仍存在争议且未得到充分利用。放疗在缓解转移性黑色素瘤症状方面非常有效。放疗与免疫治疗等新的全身治疗方法联合应用具有前景，目前正在积极评估中。
